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Endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) in hypothalamic
neurons are common features of obesity, resulting in leptin and insulin resistance. In this issue, Williams
et al. (2014) demonstrate, for the first time, cell-nonautonomous UPR signaling between brain and liver in
the context of glucoregulation.The unfolded protein response (UPR)
was discovered over 20 years ago in
S. cerevisiae as a homeostatic mecha-
nism to orchestrate protein folding and
quality control in cells undergoing endo-
plasmic reticulum (ER) stress. In recent
years, this conserved organelle house-
keeping network has been implicated in
multiple physiological functions in mam-
mals, where it plays a predominant role
in specialized secretory cells, such as
plasma B cells and pancreatic b cells
(Hetz, 2012). The most conserved UPR
stress sensor is IRE1a, a kinase and
endoribonuclease located at the ER
membrane that upon activation catalyzes
the processing of the mRNA encoding
the transcription factor XBP1. This uncon-
ventional splicing event excises a 26
nucleotide intron that shifts the coding
reading frame, leading to the expression
of an active andpotent transcription factor
known as XBP1s (Hetz, 2012). XBP1s
translocates to the nucleus and upregu-
lates a cluster of genes involved in protein
folding, quality control, lipid metabolism,
and many components of the secretory
pathway. In the context ofmetabolic regu-
lation, XBP1s is required for the differenti-
ation of pancreatic b cells and for insulin
secretion, whereas insulin resistance
causedbydiet-induced obesity in respon-
sive tissues, such as the liver and skeletal
muscle, is associated with local ER stress
(Hotamisligil, 2010). Analogously, a high-
fat diet activates the UPR in the mouse
hypothalamus, and XBP1s expression
has a protective role on leptin sensitivity
in this brain region (Ozcan et al., 2009).These findings uncovered the contribution
of the IRE1a/XBP1 branch of the UPR as
a plausible target for therapeutic interven-
tion against diet-induced leptin resistance
in the brain (Hetz and Mollereau, 2014). In
this issue of Cell Metabolism, Williams
et al. (2014) unveil a predominant role of
cell-specific hypothalamic XBP1 expres-
sion in the global control of energy bal-
ance not only through local protection
against ER stress and leptin/insulin
sensitization, but also via the unexpected
cell-nonautonomous propagation of UPR
signals along the brain-liver axis.
The hypothalamus is a central process-
ing unit where many survival signals
related to appetite, sleep, and other moti-
vational states converge to generate
the corresponding behavioral outputs.
The hypothalamic arcuate nucleus (ARC),
in particular, harbors distinct neuronal
subpopulations that control energy bal-
ance through endocrine and paracrine
signaling. Pro-opiomelanocortin (POMC)
neurons are generally considered anorex-
igenic (i.e., mediators of the central
response to satiety). They receive inhibi-
tory inputs from orexigenic agouti-related
peptide (AgRP) neurons, which are potent
drivers of feeding behavior. Both cell
types respond to insulin, leptin, glucose,
and free long-chain fatty acids, acting
as sensors of nutritional status and con-
tributing to orchestrate the behavioral,
endocrine, and metabolic responses to
hunger and satiety (Gao and Horvath,
2007). The complexity of these regulatory
networks within hypothalamic circuits is
being unraveled thanks to the develop-Cell Metabolism 20, Sment of sophisticated neurogenetic and
neuromanipulation tools.
Using organotypic cultures of murine
ARCs, Williams et al. (2014) found that
acute, pharmacologically induced ER
stress is detrimental to leptin-evoked re-
sponses in ARC-POMC neurons in mice
and provided convincing evidence that
this negative effect is mediated by the
induction of two known leptin-signaling
blockers: suppressor of cytokine
signaling 3 (SOCS3) and tyrosine phos-
phatase 1B (PTP1B). Remarkably, artifi-
cial overexpression of XBP1s selectively
in POMC neurons repressed Socs3 and
Ptp1B expression, through unknown
mechanisms, and ablated the effects of
pharmacological ER stressors on leptin
resistance. This finding not only suggests
that ER stress causally precedes leptin/
insulin resistance in the hypothalamus,
but also uncovers XBP1, and by deduc-
tion IRE1, as a promising target to amelio-
rate leptin resistance in the nervous
system and beyond (Figure 1A). Lending
physiological credence to these in vitro
observations, inducible overexpression
of XBP1s in POMC neurons had a marked
metabolic effect in mice characterized by
protection against diet-induced obesity,
improved insulin sensitivity, increased
energy expenditure, browning of adipose
tissue, and lower endogenous glucose
production by the liver. Importantly, these
pleiotropic metabolic changes appear
to be independent of food consumption,
suggesting that XBP1 expression in
ARC-POMC neurons is sufficient to
generate a global metabolic ‘‘fed state’’eptember 2, 2014 ª2014 Elsevier Inc. 385
AB
Figure 1. A New Mechanism of Hypothalamic Control of Global Energy Balance through the UPR Transcription Factor XBP1
(A) Insulin and leptin resistance in the hypothalamus is causally connected with ER stress triggered by circulating free fatty acids in models of obesity. ER stress
induces Ptp1b and Socs3, two known blockers of leptin signaling. Expression of the active form of the UPR transcription factor XBP1s in POMC neurons has
protective effects on these endocrine pathways, possibly enhancing the transmission of satiety signals to target organs and stimulating energy expenditure.
(B) Apart from its cell-autonomous effect on leptin/insulin signaling (inset), XBP1s activation in POMC neurons propagates to the liver via a cell-nonautonomous
mechanism, where XBP1 mRNA splicing by IRE1a activates canonical UPR target genes, such as Bip, Edem1, and Erdj4, and also the enzyme UDP-glucose-4-
epimerase (GALE) in hepatocytes. These events may contribute to reduced hepatic glucose release and enhanced insulin sensitivity observed in POMC-specific
inducible Xbp1s (PIXs) mice. Figure design by Dr. Gabriela Martı´nez.
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In a remarkable finding, ectopic XBP1s
overexpression in POMC neurons
induced the cell-nonautonomous activa-
tion of XBP1 mRNA splicing in the mouse
liver, where it appears to mediate a
postprandial transcriptional program.
This XBP1s-dependent program resulted
in increased levels of UDP-glucose-4-
epimerase (GalE), which led to reduced
endogenous glucose release, lower gly-
cemia, and improved insulin sensitivity,
in agreement with the phenotype of hep-
ato-specific XBP1s overexpression in
mice (Deng et al., 2013) (Figure 1B). Inter-
estingly, an analogous cell-nonautono-
mous regulatory circuit for XBP1 was
only recently described in the model or-
ganism C. elegans, where XBP1s expres-
sion in the nervous system engaged XBP1
mRNA splicing in the intestine in an IRE1-386 Cell Metabolism 20, September 2, 2014 ªdependent manner, to increase lifespan
and protect animals from ER stress (Tay-
lor and Dillin, 2013).
The present study suggests for the first
time that the basic concept of neuronal
control of ER stress might be a conserved
feature of the UPR in metazoans and
opens many intriguing questions about
the global integration of stress signals in
the modulation of diverse physiological
responses by the central nervous system
(Taylor et al., 2014). A precise definition
of this cell-nonautonomous circuit may
have enormous therapeutic potential and
can be outlined by answering: (1) What
is the signal produced by XBP1s activity
that propagates from neurons to peri-
pheral tissues? (2) Does it rely on direct
multisynaptic connection to the target
tissue, or is it relayed through secondary
downstream effectors? (3) How are the
canonical ER-stress sensors engaged2014 Elsevier Inc.during the cell-nonautonomous activation
of Xbp1 splicing? (4) Is the activation of
IRE1 in the hepatocyte stress indepen-
dent? It is possible that signaling events
may directly engage IRE1a activation
through assembling distinct UPRosome
regulatory complexes, as suggested in
other systems (Hetz, 2012). In C. elegans,
the direct release of small molecule
neurotransmitters, rather than neuropep-
tides, is required for cell non-autonomous
xbp1 mRNA splicing in the intestine. In
mammals, there are direct multisynaptic
connections between ARC-POMC neu-
rons and the liver aswell as adipose tissue
(Stanley et al., 2010), which could be
targeted in future mechanistic studies.
The work of Williams et al. provides
important implications to understand
the central control of energy balance
and identifies IRE1/XBP1 signaling in
ARC-POMC neurons as a key module
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pose tissue physiology and glucose use
by the liver through a novel UPR cell-
nonautonomous mechanism. It remains
to be shownwhether long-termmanipula-
tion of this pathway influences other func-
tional outputs of POMC neurons, but for
the time being, the specificity and cell-
type-restricted mode of action of XBP1s
in the hypothalamus can be considered
a promising therapeutic candidate to treat
prevalent metabolic diseases.
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Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease
(CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian random-
ization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.The status of plasma TG levels as a risk
factor for CHD has been debated for de-
cades. In most studies, plasma TG levels
are associated with CHD, but adjusting
for confounding variables (e.g., smoking,
insulin resistance, and diabetes) sub-
stantially attenuates the association (Di
Angelantonio et al., 2009). Two recent
studies take a genetic approach to untan-
gle the Gordian knot between TG levels
and CHD (Crosby et al., 2014; Jørgensen
et al., 2014).
Instead of stratifying individuals based
on plasma TG levels, the studies divide
participants into two groups according
to their APOC3 genotypes. Plasma
APOC3 and TG levels are highly corre-lated. Stratifying by APOC3 genotype
rather than plasma level of TG circum-
vents confounding by factors that affect
both plasma TG levels and CHD, an
approach referred to as Mendelian
randomization (Katan, 1986).
One study, led by Sekar Kathiresan,
identified four rare variants in APOC3
that were associated with a 39% reduc-
tion in plasma TG levels (Crosby et al.,
2014). The variants were then tested for
association with CHD in 110,097 individ-
uals from 15 different studies. Mutation
carriers had a 40% reduction in CHD
compared to noncarriers. The other
study, led by Anne Tybjærg-Hansen,
used a similar strategy (Jørgensen et al.,2014). They found three APOC3 variants
that were associated with a 44% reduc-
tion in plasma TG levels. In a cohort of
75,725 Danes, carriers of these variants
had a 41% reduction in CHD. Taken
together, these findings provide compel-
ling evidence that reducing APOC3
expression will reduce CHD risk. The
question remains as to whether the
reduced CHD risk in APOC3 variant
carriers is due to lower plasma TG levels
or to other associated factors, such as
lower plasma levels of LDL cholesterol
(LDL-C), APOC3, or remnant lipoproteins,
or to increased levels of HDL-C.
Reductions in LDL-C are consistently
associated with reduced CHD. Figure 1Aeptember 2, 2014 ª2014 Elsevier Inc. 387
